Coherus Oncology (CHRS) Amortizatization of Intangibles (2015 - 2023)

Coherus Oncology has reported Amortizatization of Intangibles for 9 years, with the latest figure at -$428000.0 in Q4 2023.

• Quarterly Amortizatization of Intangibles fell 153.5% year-over-year to -$428000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $726000.0 (down 85.87% YoY) and the FY2024 annual result came in at $4.2 million, up 72.79% from the prior year.
• Amortizatization of Intangibles eased to -$428000.0 in Q4 2023 per CHRS's latest filing, from $255000.0 in the prior quarter.
• Over five years, Amortizatization of Intangibles peaked at $3.7 million in Q1 2022 and troughed at -$428000.0 in Q4 2023.
• A 5-year average of $685950.0 and a median of $327000.0 in 2020 frame the typical range for Amortizatization of Intangibles.
• The sharpest annual moves came in 2019 and 2023: Amortizatization of Intangibles soared 1143.18% in 2019, then plunged 153.5% in 2023.
• Over 5 years, Amortizatization of Intangibles stood at $2.2 million in 2019, then sank by 54.98% to $989000.0 in 2020, then grew by 11.93% to $1.1 million in 2021, then declined by 27.73% to $800000.0 in 2022, then slumped by 153.5% to -$428000.0 in 2023.
• According to Business Quant data, Amortizatization of Intangibles over the past three periods registered -$428000.0, $255000.0, and $243000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.